IGF1R and breast carcinoma: The studies presented here support that IGF-IR signaling is a driver of brain metastases, with important implications in which therapeutic inhibition of this receptor may prevent or delay the establishment of IGF-IR-positive metastatic brain tumors from breast cancer.